Pulmonary Arterial Hypertension (PAH) Market in United States, United Kingdom– Market Outlook, Market Assessment and Market Forecast (2023-2030)

1. Executive Summary: Pulmonary Arterial Hypertension (PAH)
   • Global Market Outlook: Pulmonary Arterial Hypertension (PAH)
2. Competitive Intelligence Analysis: Pulmonary Arterial Hypertension (PAH)
3. Therapeutic Sector SWOT
4. Technology Roadmap Analysis: Pulmonary Arterial Hypertension (PAH)
5. Market Background
   • Drivers
   • Restraints
   • Opportunity
   • Key Market Trends
   • Key Unmet Needs
6. Disease Overview: Pulmonary Arterial Hypertension (PAH)
   • Disease Etiology
   • Pathophysiology
   • Risk Factors
   • Treatment Algorithm
7. Pulmonary Arterial Hypertension (PAH): Key Marketed Products Profile – Major Approved Products
   • Product Profile
   • Regulatory Milestones
   • Safety and Efficacy
   • Clinical Development
8. Pulmonary Arterial Hypertension (PAH): Promising Pipeline Candidates – Major Products in Late Stage of Development
   • Product Description
   • Safety and Efficacy
   • Research and Development
9. Regulatory Landscape
10. Pulmonary Arterial Hypertension (PAH): Eight Major Market (8MM) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
11. S. Pulmonary Arterial Hypertension (PAH) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
12. K. Pulmonary Arterial Hypertension (PAH) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
13. Germany Pulmonary Arterial Hypertension (PAH) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
14. France Pulmonary Arterial Hypertension (PAH) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
15. Italy Pulmonary Arterial Hypertension (PAH) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
16. Spain Pulmonary Arterial Hypertension (PAH) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
17. Japan Pulmonary Arterial Hypertension (PAH) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
18. China Pulmonary Arterial Hypertension (PAH) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
19. Competitive Landscape
    • Company Overview
    • Product Portfolio
    • Key Financials
    • Sales Footprint

Note – All Major Company Profiles (Count up to 20) will be covered in the report

20. Assumptions and Acronyms Used
21. Research Methodology
    • Secondary Research
    • Primary Research
    • Data Triangulation
22. Geographic Scope
    • The U.S., The U.K., Germany, France, Italy, Spain, Japan, and China
23. Copyrights and Disclaimer

Pulmonary Arterial Hypertension (PAH) – Report Overview

Pacific Business Consulting’s “Pulmonary Arterial Hypertension (PAH) Market in 8MM – Market Outlook, Market Assessment and Market Forecast (2023-2030)” report offers a comprehensive exploration of Pulmonary Arterial Hypertension, encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Eight Major Markets (8MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and China.

The global market for pulmonary arterial hypertension (PAH) was valued at US$ 5.4 Billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of more than 5% from 2023 to 2030. Key drivers of this market include growing initiatives by major market players, a high prevalence of pulmonary arterial hypertension, adoption rates, availability of reimbursement, and the entry of generics.

Pulmonary arterial hypertension is a rare and progressive disorder characterized by hypertension in the pulmonary arteries without an apparent cause. It is defined by the 6th World Symposium on Pulmonary Hypertension (WSPH) as a resting mean pulmonary artery pressure (mPAP) of 20 mm Hg or greater, a normal end-expiratory pulmonary artery wedge pressure (PAWP) less than or equal to 15 mm Hg, and a pulmonary vascular resistance (PVR) greater than or equal to 3 Wood units. The World Health Organization (WHO) further classifies PAH into types, including idiopathic PAH (IPAH), heritable PAH (HPAH), drug and toxin-induced PAH, and PAH associated with other diseases and disorders such as cirrhosis, HIV, congenital heart disease, and connective tissue diseases like scleroderma.

Current mainstay therapies for the treatment of PAH target the three major pathways: NO/cGMP, endothelin, and prostacyclin. These therapies include PDE5 inhibitors, sGC stimulators, ERAs, prostacyclin analogs, and agonists.

Key players in the Pulmonary Arterial Hypertension market include Bayer Group, Acceleron, Gilead Sciences, Aerovate Therapeutics, CMP Pharma, Cereno Scientific AB, Eli Lilly, Gilead, GlaxoSmithKline, Johnson & Johnson, and Actelion Pharmaceuticals.

Scope of Report

The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the Pulmonary Arterial Hypertension (PAH) market. It also delves into the analysis of present and prospective market competition within the Pulmonary Arterial Hypertension (PAH) market.

Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.

Reasons to Buy

• Develop your business strategies by gaining insights into the trends that shape and drive the Pulmonary Arterial Hypertension (PAH) market across the 8MM (Eight Major Markets).
• Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 8MM Pulmonary Arterial Hypertension (PAH) market.
• Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
• Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.

Please note that detailed pipeline analysis can be provided along with the standard scope to assist you in developing and designing your in-licensing and out-licensing strategies. This includes a review of pipeline products and technologies, along with identifying companies with the most robust pipeline.